Cannabis research: where Ayurveda meets modern science

Where ancient Ayurveda and modern science meet on cannabis

Cannabis has two lives in India. The first is ancient.

Classical Ayurvedic physicians wrote about a plant they called Vijaya (cannabis, also referred to in some texts as hemp) thousands of years ago, noting its effects on the mind and body with the same careful attention they gave to hundreds of other medicinal plants. The second life is recent.

Over the past two decades, pharmacologists, sleep researchers, and neuroscientists around the world have published hundreds of peer-reviewed studies on cannabis compounds, trying to understand exactly how they interact with human biology.

Most people treat these two lives as separate. Ayurveda belongs to tradition; research belongs to laboratories. This article argues that the separation is less clean than it looks.

The questions Ayurvedic physicians were asking, about how cannabis supports calm, rest, and relief from everyday discomfort, turn out to be close to the questions modern researchers are asking too.

That parallel does not mean every ancient claim has been confirmed. It has not. The evidence is still developing, and this article will be honest about its limits.

What it does mean is that a curious Indian adult asking about cannabis research today has access to two bodies of knowledge, one rooted in millennia of clinical observation, one rooted in controlled trials, and both are worth understanding before making any personal decision.

Any personal decision belongs with a qualified physician. This article informs. It does not prescribe. Specific health situations should be discussed with a doctor, and Calmosis offers a free doctor consultation for exactly that purpose.

What Ayurveda has said about Vijaya for centuries

Vijaya appears in Ayurvedic literature as far back as the Atharva Veda, one of the four sacred Vedic texts, where it is listed among plants considered protective.

The more clinically detailed classical texts, the Charaka Samhita and the Sushruta Samhita, compiled over several centuries with roots scholars date to roughly 600 BCE and later redactions extending into the early centuries CE, describe cannabis preparations used to support digestive function, reduce restlessness, and ease discomfort.

The Sharangadhara Samhita, a 13th-century pharmacological text, gives more specific formulation guidance and notes the plant's sedative properties.

Ayurvedic physicians classified Vijaya according to the system of gunas (qualities) and doshas (the three constitutional energies, Vata, Pitta, and Kapha, that Ayurveda uses to describe physiology). Vijaya was considered to have tikta (bitter) and kashaya (astringent) tastes, with heating potency.

Classical practitioners used it in small, carefully calibrated doses as part of compound formulations, rarely as a standalone herb, and always under supervision. The emphasis on dose and supervision is not incidental.

It reflects a consistent theme across classical Ayurvedic writing on Vijaya: the plant is potent, and its effects depend heavily on how it is prepared and administered.

Traditional indications recorded across these texts include support for sleep, relief from everyday physical discomfort, calming of mental restlessness, and support for appetite. These are not disease-cure claims.

Ayurvedic texts frame them as effects observed in practice over generations, used to support the body's natural balance rather than to treat named conditions in the pharmaceutical sense.

Today, India's Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy) has formally recognized Vijaya as a medicinal plant under the Ayurvedic Pharmacopoeia of India. AYUSH-certified Vijaya formulations are legal, regulated, and required to meet defined quality and safety standards.

This regulatory recognition gives classical Ayurvedic use a contemporary institutional home, which matters for a cautious buyer who wants to know that a product sits within a recognized framework rather than a legal gray area.

How cannabis works in the body: the endocannabinoid system explained simply

To understand why cannabis research has attracted so much scientific attention, it helps to know about a signaling network inside the human body that researchers did not discover until the early 1990s.

They named it the endocannabinoid system (ECS), a network of receptors, signaling molecules, and enzymes that the body uses to regulate a wide range of processes including mood, sleep, appetite, and the perception of discomfort.

The ECS has two main receptor types, called CB1 and CB2. CB1 receptors are found mainly in the brain and central nervous system. CB2 receptors are found mainly in immune tissues and the peripheral nervous system.

The body produces its own molecules, called endocannabinoids, that bind to these receptors as part of normal physiological regulation. The most studied endocannabinoids are anandamide and 2-AG (2-arachidonoylglycerol).

Cannabis contains dozens of compounds called cannabinoids. The two most studied are THC (tetrahydrocannabinol) and CBD (cannabidiol). THC binds directly to CB1 receptors and produces the psychoactive effects associated with cannabis. CBD does not bind directly to CB1 or CB2 receptors in the same way.

Researchers believe CBD influences the ECS more indirectly, including by slowing the breakdown of the body's own endocannabinoids, which may prolong their regulatory effects.

The discovery of the ECS gave researchers a biological framework for investigating why cannabis has effects on sleep, mood, and discomfort. It also gave Ayurvedic scholars a reason to revisit classical observations with fresh eyes.

When an ancient text notes that Vijaya reduces restlessness, a modern researcher can now ask whether that observation corresponds to CB1 activity in the brain regions that regulate anxiety responses. The frameworks are different, but the questions overlap.

It is worth being clear about what this does not mean. Identifying a biological mechanism is not the same as proving a clinical outcome. The existence of the ECS explains why cannabis compounds have effects; it does not confirm that any specific product will produce a specific result in any specific person.

That determination belongs with a physician.

Key areas modern research has explored

Cannabis research has grown substantially since the early 2000s, driven partly by shifting legal rules in North America and Europe and partly by the discovery of the ECS.

The following areas are where peer-reviewed research has been most active and where findings are most relevant to the everyday concerns of Indian adults considering Vijaya formulations.

Sleep support

Several studies have examined whether cannabinoids may support sleep onset and duration. A review published in Current Psychiatry Reports surveyed existing literature and found that CBD may support sleep in people experiencing disrupted rest, though the authors noted that evidence quality was mixed and that more controlled trials were needed.

A 2021 study in the Journal of Clinical Medicine found that participants using cannabis reported improvements in self-assessed sleep quality, though the study relied on self-report and lacked a placebo control, limiting its conclusions.

The current evidence suggests cannabis compounds may support restful sleep in some individuals; it does not confirm that they will do so reliably across populations.

Stress response

Research on CBD and the body's stress response has focused on the hypothalamic-pituitary-adrenal (HPA) axis, the system that governs cortisol release. A 2019 study in the Brazilian Journal of Psychiatry found that a single dose of CBD reduced subjective anxiety in participants exposed to a simulated public-speaking task, compared to placebo.

The effect was dose-dependent, with both very low and very high doses showing weaker effects than a moderate dose. Researchers describe this as preliminary evidence that CBD may support a calmer stress response; they do not describe it as proof of a treatment for anxiety disorders.

Everyday physical discomfort

The area with the largest body of research is pain, specifically neuropathic and inflammatory discomfort.

A 2018 review in Frontiers in Pharmacology examined preclinical and clinical studies and concluded that cannabinoids show promise for supporting relief from certain types of physical discomfort, with CB1 and CB2 receptor activity appearing to modulate pain signaling pathways.

Clinical evidence in humans remains less consistent than preclinical findings, and most reviewed studies used pharmaceutical-grade cannabinoids at controlled doses rather than over-the-counter wellness formulations. The relevance to a Vijaya wellness oil is therefore indirect and should be interpreted cautiously.

Across all three areas, the pattern is similar. There is enough evidence to take the questions seriously and enough uncertainty to require professional guidance before any individual acts on the research.

What the research does not yet confirm

Honest cannabis research communication requires equal attention to what the evidence does not support. Several widely held beliefs about cannabis compounds have not held up well under rigorous scrutiny, and a reader deserves to know this.

NPR reported on a large analysis examining whether cannabis or cannabinoids provided meaningful benefit for anxiety and depression. The analysis found no strong evidence that cannabis products reliably reduce symptoms of anxiety or depression in clinical populations.

The researchers noted that many existing studies were small, short-term, and methodologically inconsistent, making it difficult to draw firm conclusions in either direction. This does not mean cannabis has no effect on mood.

It means the current evidence base is not strong enough to support confident claims, and that anyone managing anxiety or depression should rely on qualified medical care rather than wellness products.

Several other areas of uncertainty are worth naming directly. Most cannabis research has been conducted in North American or European populations using pharmaceutical-grade isolates, not Ayurvedic formulations prepared with traditional methods. The compounds, doses, delivery methods, and populations differ significantly from what an Indian adult using a Vijaya oil would experience.

Extrapolating directly from those studies to a Calmosis formulation requires caution.

Long-term safety data for regular cannabinoid use in healthy adults remains limited. Most studies run for weeks or months, not years. Interactions between cannabis compounds and common medications, including those for blood pressure, thyroid conditions, and blood thinning, are documented but not fully characterized.

This is another reason why a physician consultation is not optional advice. It is a practical safety step.

Finally, individual response to cannabis compounds varies considerably. Factors including body weight, metabolic rate, existing health conditions, and concurrent medications all influence how a person responds. No article can predict an individual outcome. That is the physician's role.

Comparing traditional Ayurvedic uses with modern research findings

The table below maps classical Ayurvedic indications for Vijaya against the closest area of modern cannabis research, the current strength of that evidence, and how Calmosis frames the use. It is a reference tool, not a clinical guide.

Gaps and mismatches are included deliberately, because honesty about what is not yet confirmed is as important as noting where tradition and science align.

How India's AYUSH framework shapes Vijaya products today

India's regulatory approach to Vijaya sits within the AYUSH framework rather than the pharmaceutical drug approval system overseen by the Central Drugs Standard Control Organisation (CDSCO). Understanding the difference matters for any cautious buyer.

A pharmaceutical drug approval in India requires the manufacturer to demonstrate safety and efficacy through clinical trials conducted to defined regulatory standards, after which the drug is approved for specific indications. The approval is indication-specific. A drug approved for one condition cannot legally be marketed for another.

AYUSH certification operates differently. It recognizes that Ayurvedic formulations have a documented history of traditional use recorded in classical texts and the Ayurvedic Pharmacopoeia of India. AYUSH-certified products must meet defined standards for ingredient quality, manufacturing practice, and labeling. They must not make disease-cure claims.

They are certified as Ayurvedic wellness formulations with traditionally recognized uses, not as pharmaceutical drugs approved for specific medical conditions.

For Vijaya specifically, the AYUSH Ministry has recognized cannabis as a medicinal plant under the Ayurvedic Pharmacopoeia. Licensed manufacturers can produce Vijaya-based formulations under AYUSH rules.

These products must use hemp-derived ingredients within legally permitted THC limits, follow Good Manufacturing Practice (GMP) standards, and carry labels that comply with AYUSH advertising guidelines, which prohibit the kind of cure and treatment claims this article has been careful to avoid.

What AYUSH certification means for a cautious buyer is this. It means the product comes from a regulated supply chain, not an uncontrolled source. It means the formulation has a documented traditional basis. It means the manufacturer is accountable to a government body.

It does not mean the product is equivalent to a pharmaceutical drug, and it does not mean it is appropriate for every individual. A physician consultation remains the right next step before starting any new wellness formulation, including an AYUSH-certified Vijaya oil.

What to ask a doctor before trying a Vijaya formulation

The research and tradition covered in this article can help a reader form better questions. It cannot replace the conversation those questions belong in.

Before starting any Vijaya formulation, a physician consultation is the right step, not a precaution for people with serious conditions only, but a practical step for any adult who wants to use the product safely and appropriately.

The following questions are worth raising with your doctor. Calmosis offers a free doctor consultation with a qualified physician who can work through these with you.

• Do any of my current medications interact with cannabinoids? Documented interactions exist with blood thinners, some blood pressure medications, and certain thyroid medications, among others. Your doctor should review your full medication list.
• Is a Vijaya formulation appropriate given my existing health conditions? Some conditions require caution or make cannabis-based products unsuitable. This is a clinical judgment, not something an article can answer.
• What dose and formulation would be appropriate for my situation? Ayurvedic texts consistently emphasize that dose determines effect. Your physician should guide you on starting doses and how to assess your response.
• How long should I try a formulation before assessing whether it is supporting my goal? Wellness formulations often require consistent use over weeks. Your doctor should help you set a realistic assessment timeline.
• Are there lifestyle factors, diet, or other Ayurvedic practices that would complement a Vijaya formulation? Ayurveda treats the whole person. A physician familiar with both classical practice and modern evidence can give you a fuller picture.
• If I have a specific condition I am hoping to address, is a Vijaya formulation the right tool, or is there a more evidence-supported option? Specific health conditions require specific clinical guidance. A wellness formulation is not a substitute for appropriate medical care.

If you are managing a named health condition, experiencing significant symptoms, or taking prescription medication, please route that conversation directly to a qualified physician. The Calmosis free doctor consultation is designed for exactly this kind of personalized discussion.